HeimBiotek Transfers Technology to Prevent False Positive PCR Results
HeimBiotek announced on the 16th that it has signed a technology transfer agreement with the National Fisheries Products Quality Management Service (NFQS) under the Ministry of Oceans and Fisheries.
Through this agreement, HeimBiotek will receive the patented technology from NFQS, an OIE standard laboratory, to prevent false positive reactions in PCR (Polymerase Chain Reaction) tests. PCR is a method that amplifies and detects specific target DNA, enabling the mass amplification of identical DNA from very small amounts.
The patented technology transferred from NFQS is designed to determine false positive reactions that can occur during the diagnosis of White Spot Syndrome Virus (WSSV) in shrimp, which causes significant damage to the global shrimp farming industry, due to contamination of the positive control DNA.
HeimBiotek plans to utilize this technology to develop a COVID-19 diagnostic kit that can solve the issue of misdiagnosis caused by false positives.
HeimBiotek's CEO stated, "We aim to minimize the possibility of misdiagnosis with a COVID-19 diagnostic kit incorporating technology to identify false positive reactions and hope to widely disseminate this highly reliable diagnostic technology to other countries."
The NFQS director promised, "We will provide unwavering support to ensure that the developed diagnostic technology enhances the reliability of COVID-19 test kits, enabling more thorough quarantine measures based on accurate testing."
This content is partially excerpted from a news article.
